OBJECTIVES: The medical management of men with Lower Urinary Tract Symptoms often involves agents targeting bladder outlet obstruction (BOO) such as α-blockers or 5-α reductase inhibitors (5ARI).  However, overactive bladder (OAB) symptoms may coexist with BOO.  This study aims to describe the baseline characteristics of men who utilize OAB [mirabegron and antimuscarinics (AM)] therapy and sequential and combination use of various urologic medication classes. METHODS: Data from a US commercial database were analyzed for men starting OAB therapy between 10/01/12 and 12/31/13. Men were grouped by initiation of mirabegron or AM.  A 12-month retrospective analysis was conducted with patients defined as naïve or experienced to AM therapy 12-month period prior to index. Baseline demographics and comorbid conditions were compared. Concomitant BOO medications, in use at baseline, initiated, or discontinued during the 90 days pre/post index date of mirabegron or AM, were analyzed. RESULTS: More men on mirabegron saw a urologist (75% vs 35%), more likely to have BOO diagnosed (66% vs 49%) and use in free combination with α-blockers (26% vs 17%) and 5ARI (7% vs 4%) therapy versus AM. Baseline characteristics showed mirabegron patients were older (64 vs 59) and had a higher Elixhauser comorbidity index (4.7 vs 4.0) compared with AM patients. Baseline health resource utilization (HRU) was higher among the mirabegron cohort for urodynamic (58% vs 29%), cystoscopy (25% vs 19%), polypharmacy (10.4 vs. 8.2) and overall outpatient visits (11.4 vs 8.5). More mirabegron patients had prior prostate (7.6% vs 5.8%) and OAB (3.9% vs 0.7%) surgical therapy 12-months prior to index compared to AM patients. CONCLUSIONS: Male patients receiving mirabegron showed distinct baseline characteristics. Patients managed by urologists were often more complicated with greater baseline HRU. Additional studies to model the impact of patient characteristics on outcomes in those prescribed mirabegron and AMs may be helpful.